1. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). (February 2021) Authors: Tanzawa, Shigeru; Ushijima, Sunao; Shibata, Kazuhiko; Shibayama, Takuo; Bessho, Akihiro; Kaira, Kyoichi; Misumi, Toshihiro; Shiraishi, Kenshiro; Matsutani, Noriyuki; Tanaka, Hisashi; Inaba, Megumi; Haruyama, Terunobu; Nakamura, Junya; Kishikawa, Takayuki; Nakashima, Masanao; Iwasa, Keiichi; Fujiw... Journal: Therapeutic advances in medical oncology Issue: Volume 13(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. (December 2022) Authors: Tanaka, Hisashi; Tanzawa, Shigeru; Misumi, Toshihiro; Makiguchi, Tomonori; Inaba, Megumi; Honda, Takeshi; Nakamura, Junya; Inoue, Koji; Kishikawa, Takayuki; Nakashima, Masanao; Fujiwara, Keiichi; Kohyama, Tadashi; Ishida, Hiroo; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hirosh... Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. (November 2021) Authors: Noro, Rintaro; Igawa, Satoshi; Bessho, Akihiro; Hirose, Takashi; Shimokawa, Tsuneo; Nakashima, Masanao; Minato, Koichi; Seki, Nobuhiko; Tokito, Takaaki; Harada, Toshiyuki; Sasada, Shinji; Miyamoto, Shingo; Tanaka, Yosuke; Furuya, Naoki; Kaburagi, Takayuki; Hayashi, Hideki; Iihara, Hirotoshi; Okam... Journal: Lung cancer Issue: Volume 161(2021) Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. (March 2016) Authors: Hirose, Takashi; Fujita, Ken-ichi; Kusumoto, Sojiro; Oki, Yasunari; Murata, Yasunori; Sugiyama, Tomohide; Ishida, Hiroo; Shirai, Takao; Nakashima, Masanao; Yamaoka, Toshimitsu; Okuda, Kentaro; Ohmori, Tohru; Sasaki, Yasutsuna Journal: Lung cancer Issue: Volume 93(2016) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. (March 2016) Authors: Hirose, Takashi; Fujita, Ken-ichi; Kusumoto, Sojiro; Oki, Yasunari; Murata, Yasunori; Sugiyama, Tomohide; Ishida, Hiroo; Shirai, Takao; Nakashima, Masanao; Yamaoka, Toshimitsu; Okuda, Kentaro; Ohmori, Tohru; Sasaki, Yasutsuna Journal: Lung cancer Issue: Volume 93(2016) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). (July 2022) Authors: Tanzawa, Shigeru; Makiguchi, Tomonori; Tasaka, Sadatomo; Inaba, Megumi; Ochiai, Ryosuke; Nakamura, Junya; Inoue, Koji; Kishikawa, Takayuki; Nakashima, Masanao; Fujiwara, Keiichi; Kohyama, Tadashi; Ishida, Hiroo; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hiroshi; Oda, Naohiro; ... Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗